Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apricitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.59 |
| ▸ | ALB | P02768 | 3/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.59 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | POLG | P54098 | 2/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apricitabine SCHEMBL1751974 | 1.00 | LMNA (0.59) | LMNAPDE3AALBCACNA1FMAPT | |
| Apricitabine SCHEMBL10078436 | 1.00 | LMNA (0.59) | LMNAPDE3AALBCACNA1FMAPT | |
| Apricitabine SCHEMBL12225360 | 1.00 | LMNA (0.59) | LMNAPDE3AALBCACNA1FMAPT | |
| Apricitabine SCHEMBL1751976 | 1.00 | LMNA (0.59) | LMNAPDE3AALBCACNA1FMAPT | |
| Apricitabine SCHEMBL5556340 | 0.99 | LMNA (0.58) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL12530007 | 0.84 | LMNA (0.43) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL12530009 | 0.84 | LMNA (0.43) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL12529929 | 0.84 | LMNA (0.43) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL15788455 | 0.84 | LMNA (0.45) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL12224210 | 0.84 | LMNA (0.45) | LMNAPDE3AALBCACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1374 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260021101-A1 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE-ASSOCIATED INFLAMMATION AND DISORDERS | BROWN UNIVERSITY (US) | 2026-01-22 | — | — | US | claimed |
| US-12496282-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20250283074-A1 | CLUSTERIN OVEREXPRESSION IN ALZHEIMER’S DISEASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-09-11 | — | — | US | claimed |
| US-20220110963-A1 | REVERSE TRANSCRIPTASE BLOCKING AGENTS AND METHODS OF USING THE SAME | THE GENERAL HOSPITAL CORPORATION | 2022-04-14 | — | — | US | claimed |
| EP-3976614-A1 | DI-FLUORO AZEPANES AS HBV CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | claimed |
| EP-3976613-A1 | AZEPINES AS HBV CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | claimed |
| EP-3976619-A1 | FUSED HETEROCYCLE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | claimed |
| EP-3963087-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | Illumina Inc (US) | 2022-03-09 | — | — | EP | claimed |
| CN-114040781-A | Formulation of conjugate of TUBULYSIN derivative and cell binding molecule | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| US-11234981-B2 | Combination therapy for use in treating retroviral infections | CIPLA LIMITED (IN) | 2022-02-01 | — | — | US | claimed |
| US-7968703-B2 | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof | SHIRE CANADA INC. (CA) | 2011-06-28 | — | — | US | claimed |
| EP-1866303-A1 | PROCESS AND METHODS FOR THE PREPARATION OF OPTICALLY ACTIVE CIS-2-HYDROXYMETHYL-4-(CYTOSIN-1´-YL)-1,3-OXATHIOLANE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Shire BioChem Inc. (CA) | 2007-12-19 | — | — | EP | claimed |
| WO-2006096954-A1 | PROCESS AND METHODS FOR THE PREPARATION OF OPTICALLY ACTIVE CIS-2-HYDROXYMETHYL-4-(CYTOSIN-1´-YL)-1,3-OXATHIOLANE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SHIRE BIOCHEM INC. (CA) | 2006-09-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | FCGR2A, FCGR3B, FCGR1A | LMNA 4284/4885PDE3A 4123/4885ALB 302/4885 |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | LMNA 1661/4885PDE3A 4762/4885ALB 3481/4885 |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | LMNA 2109/4885PDE3A 4661/4885ALB 521/4885 |
| US-11234981-B2 | Combination therapy for use in treating retroviral infections | PAICS, HAVCR2, THPO | LMNA 3047/4885PDE3A 3163/4885ALB 516/4885 |
| US-20220110963-A1 | REVERSE TRANSCRIPTASE BLOCKING AGENTS AND METHODS OF USING THE SAME | RNGTT, POLRMT, RNASE1 | LMNA 2522/4885PDE3A 3754/4885ALB 4550/4885 |
| US-20260021101-A1 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE-ASSOCIATED INFLAMMATION AND DISORDERS | TPMT, HPRT1, APRT | LMNA 1066/4885PDE3A 1399/4885ALB 3859/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | LMNA 852/4885PDE3A 4702/4885ALB 1902/4885 |
| US-12496282-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | LMNA 453/4885PDE3A 1850/4885ALB 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.